Evidence map›Paper›PMID 36275372›Full record

ArticleProcedia computer science2022

COVID-19 antibody level analysis with feature selection approach.

Wiesław Paja, Krzysztof Pancerz, Catalin Stoean

Abstract read
In one paragraph

Article in Procedia computer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wiesław PajaCollege of Natural Sciences, University of Rzeszów, Rzeszów, Poland.
Krzysztof PancerzInstitute of Technology and Computer Science, Academy of Zamosc, Poland.
Catalin StoeanUniversity of Craiova, Department of Computer Science, Craiova, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study presented here considers the analysis of a medical dataset for the identification of the stage of onset of COVID-19 coronavirus. These data, presented in previous work by the authors, have been subjected to extensive analysis and additional calculations. The data were obtained by analyzing blood samples of infected individuals at 1, 3, and 6 months after COVID-19 infection. Results were obtained from FTIR spectrometry experiments. The results indicate a very effective ability to identify the different states of infection, and between 1 and 6 months even perfect. Specific spectrometry wavelength ranges can also be distinguished as medical markers.

Indexed as

computer aided medical diagnosisCOVID-19feature selectionFourier Transform Infrared spectrometryFTIR

Identifiers

PMID36275372
PMCPMC9578923

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.